# SILtuximab in Viral ARds (SILVAR) Study

> **NCT04616586** · PHASE3 · TERMINATED · sponsor: **RECORDATI GROUP** · enrollment: 555 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome
- Lung Diseases
- Pneumonia
- Respiratory Tract Infections
- Respiratory Tract Disease

## Interventions

- **DRUG:** Siltuximab
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT04616586
- **Lead sponsor:** RECORDATI GROUP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-13
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 555 (ACTUAL)
- **Why stopped:** The REMAP-CAP and RECOVERY substudy results appear to support the survival benefit of tocilizumab in corticosteroid-treated or untreated patients with critically ill COVID-19-associated ARDS.
- **Last updated:** 2021-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04616586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04616586, "SILtuximab in Viral ARds (SILVAR) Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04616586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*